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Abstract 
The effect of replacing a single codon in the N-terminal of human aryl sulfotransferase (HAST) 
1 and 3 with one that is more commonly found in E. coli genes was assessed. The pKK233-2 E. 
coli expression vector was employed and the polymerase chain reaction (PCR) was used to 
introduce the 5′ nucleotide substitution, at the same time maintaining the fidelity of the amino 
acid sequence. The data indicates that this change had a minimal effect on protein production, 
subcellular localization or, in the case of HAST3, catalytic activity. In general, the pKK233-2 E. 
coli vector has been less than optimal for expressing human sulfotransferase cDNAs.  
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Introduction 
Sulfate conjugation is an important pathway in the biotransformation of numerous xeno- and endobiotics such as 
drugs, hormones, bile acids and neurotransmitters. The reaction is catalysed by the sulfotransferases, a family of 
structurally and functionally related enzymes. To date, at least seven distinct human sulfotransferases have been 
characterised which differ in their primary sequence and substrate specificities. These include five aryl 
sulfotransferases, a hydroxysteroid sulfotransferase and an estrogen sulfotransferase [1]. In our laboratory, five 
human aryl sulfotransferase (HAST) cDNAs have been cloned (HAST1, HAST2, HAST3, HAST4 and HAST4v) 
[2, 3, 4]. HAST1 and HAST2 are thermostable forms of aryl sulfotransferases and sulfonate small phenolic 
compounds such as p-nitrophenol. The cDNAs which encode these proteins are identical in their coding sequence 
but differ in the 5′  untranslated  regions  [2,  3].  HAST3,  a  thermolabile  form of  aryl  sulfotransferase  is  93% 
identical in its coding sequence to HAST1 and HAST2. The monoamine dopamine is the preferred substrate of 
HAST3 [3, 5]. Recently we have cloned two cDNAs which we have termed HAST4 and HAST4v [4]. These allelic 
variants share 97 and 94% sequence homology with HAST1 and HAST3, respectively [4]. While p-nitrophenol is 
the preferred substrate for both HAST4 and HAST4v the latter has at least a 10-fold lower Km for this substrate as 
well as for the co-factor 3′‐phosphoadenosine‐5′‐phosphosulfate (PAPS) [4]. 
While multiple forms of human sulfotransferases have been shown to exist, the structural features that 
determine their substrate and co-factor (PAPS) preference are yet to be elucidated. To date no crystal structure is 
available for any sulfotransferases and this has limited our understanding of the structural and functional 
relationships of these enzymes. In order to fully characterise the different isoforms of sulfotransferases, structural 
studies are required, necessitating large amounts of functional protein. Purification of sulfotransferases from human 
tissues has a number of technical limitations, such as the availability of tissue in sufficient quantity, the inability to 
separate closely related forms and the differential stability of various forms. In the case of other xenobiotic 
metabolising enzymes, the use of heterologous expression systems has overcome many of these difficulties. The 
transient or stable expression of xenobiotic metabolising enzyme cDNAs in mammalian cells (COS cells, vaccinia 
virus systems or lymphoblastoid cell lines) has enabled important functional studies to be carried out on the proteins 
they encode. However, the major disadvantage of these systems is that the level of protein expression is too low to 
support serious structural studies. In contrast, the Escherichia coli expression system offers a higher potential 
enzyme yield [6]. Although bacteria do not usually carry out post-translational modification of proteins in the same 
manner as eukaryotes, this has not been a limitation with most xenobiotic metabolising enzymes. 
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The aim of the current study was to optimise an E. coli expression system for sulfotransferases to allow 
high level protein expression. Other investigators [7] have also used this system to express sulfotransferases but only 
a limited analysis of factors that influence the level of recombinant protein expression has been reported. Numerous 
studies conducted with other xenobiotic metabolising enzymes have attempted to maximise the levels of 
recombinant protein by manipulating factors thought to influence transcription and translation rate and efficiency, 
mRNA and protein stability, and host toxicity due to the expressed protein. In particular, modifications to the N-
terminal nucleotide sequence have been shown to improve the yields of some recombinant proteins [7]. 
 
Materials and Methods 
 
In this study, we assessed the effect on expression in E. coli of introducing a single mutation into the N-terminal 
sequence of HAST1 and HAST3 cDNAs thereby replacing an uncommon E. coli codon with one that is more 
commonly found in E. coli genes. PCR was used to introduce the ‘preferred codon’ mutation into a short fragment 
of the 5′ coding sequence. Two PCR primers were designed: the first (5′-
AATGAGCTCAGGACCATGGAGCTGATCCAGGAC-3′) was designed to encode the common native HAST1 
and HAST3 sequence and a 5′ Nco1 site; and the second (5′-
AATGAGCTCAGGACCATGGAACTGATCCAGGAC-3′) was designed to introduce the preferred codon mutation 
but encoding the same amino acid sequence. Fragments containing the 3′ coding sequences of the sulfotransferases 
were obtained from the relevant cDNAs cloned into the mammalian expression vector pCMV5. The two fragments 
were then cloned into the bacterial expression vector pKK233-2 and used to transform DH5αF’IQ™ E. coli strain. 
Transformants were selected with ampicillin and used to inoculate liquid cultures. Protein expression was induced 
with isopropyl-β- -thiogalactopyranoside (IPTG). Cells were harvested after 24 h, treated with lysozyme and 
sonicated, and subcellular fractions were prepared by differential centrifugation as described previously [8]. 
An immunoblot of subcellular fractions prepared from a typical expression trial are seen in Fig. 1. HAST1 
and HAST3 proteins were detected in the 10 000×g pellet (containing cellular debris and inclusion bodies), 
180 000×g pellet (intracellular membranes) and 180 000×g supernatant (soluble fraction). The E. coli-expressed 
HAST1 and HAST3 proteins demonstrated similar electrophoretic migration to the COS cell-expressed HAST1 and 
HAST3 proteins (Fig. 1) which migrate with molecular weights of 32 and 34 kDa, respectively [5]. The co-
migration of the E. coli and COS cell-expressed HAST1 and HAST3 supports the idea that the sulfotransferases do 
not undergo any post-translational modifications in mammalian systems that would distinguish them from the E. 
coli-expressed proteins. An interesting finding was the high levels of expression observed in controls cultured in the 
absence of the inducer IPTG (Fig. 1). This suggests that expression controlled from the trc promoter was not 
completely repressed in the absence of inducer despite the use of the DH5αF’IQ™ strain of E. coli which 
overproduces the lacIq repressor. Little difference was observed on visible inspection of blots between the 
expression levels of native and modified HAST proteins suggesting that overall protein expression was not 
significantly improved by modifying the N-terminal sequence at the second amino acid, however, no attempt was 
made to quantify protein levels. Similarly, no visible difference was observed between the subcellular localisation of 
expressed proteins. While N-terminal modifications have been shown to be important in enhancing P450 expression 
in E. coli, particular modifications have failed to produce consistent effects [8]. The present study involved only a 
single mutation at the second position and it is possible that further mutations in this region may alter expression 
levels. In more recent studies we have found that the use of the expression vector pET-3a which is controlled by the 
T7 RNA polymerase promoter [9], facilitated the production of significantly higher levels of both HAST1 and 
HAST3 protein when expressed in BL21(DE3) E. coli cells (unpublished results).  
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Fig. 1. Immunoblot of E. coli-expressed HAST1 and HAST3. Bacteria were cultured for 24 h at 30°C with 1 mM 
IPTG and subcellular fractions were prepared as described previously [8]. Lanes 1 and 2, 50 μg of total protein from 
COS cells transfected with pCMV5/HAST1 and pCMV5/HAST3, respectively [2, 3]. Lane 3–9, cytosol from E. coli 
cells transformed with: lane 3, pKK233-2 (154 μg); lanes 4 and 5, pKK233-2/HAST1 (native sequence (NS); 53 μg) 
and pKK233-2/HAST3 (NS; 131 μg) which were cultured in the absence of IPTG; lane 6, pKK233-2/HAST1 (NS; 
58 μg); lane 7, pKK233-2/HAST3 (NS; 196 μg); lane 8, pKK233-2/HAST1 (preferred codon (PC); 38 μg); lane 9, 
pKK233-2/HAST3 (PC; 106 μg).  
The functional characteristics of E. coli-expressed HAST1 and HAST3 proteins were 
determined towards their model substrates p-nitrophenol and dopamine, respectively, using a 




In the case of E. coli-expressed HAST3 (native protein) the Km for dopamine sulfonation was 
similar to COS cell-expressed HAST3 (Table 1). However, HAST3 protein containing the 
preferred sequence showed a marginally lower Km and an approximately 3-fold higher Vmax. The 
higher Vmax may have reflected an increase in active enzyme expression in the preferred codon 
construct. The determination of E. coli-expressed HAST1 activity towards its model substrate, p-
nitrophenol, was complicated by high background activity observed in the absence of substrate 
(data not shown). These studies suggested the presence of an endogenous substrate in bacterial 
cytosol, possibly a small phenolic compound which may exhibit a high affinity for HAST1. This 
background activity complicated functional characterisation of E. coli-expressed HAST1 protein 
and further studies with this form may require purification of the expressed protein.  
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Table 1. Michaelis–Menten parameters for the sulfonation of dopamine by E. coli-expressed HAST3 and COS cell-




1. B.A. Rikke and A. Roy, Structural relationships among members of the mammalian sulfotransferase gene family. 
Biochim. Biophys. Acta 1307 (1996), pp. 331–338.  
2. X. Zhu, M.E. Veronese, L.N. Sansom and M.E. McManus, Molecular characterisation of a HAST cDNA. 
Biochem. Biophys. Res. Commun. 192 (1993), pp. 671–676.  
3. X. Zhu, M.E. Veronese, C.C.A. Bernard, L.N. Sansom and M.E. McManus, Identification of two human brain 
aryl sulfotransferase cDNAs. Biochem. Biophys. Res. Commun. 195 (1993), pp. 120–127.  
4. X. Zhu, M.E. Veronese, P. Iocco and M.E. McManus, cDNA cloning and expression of a new form of HAST. Int. 
J. Biochem. Cell Biol. 28 (1996), pp. 565–571.  
5. M.E. Veronese, W. Burgess, X. Zhu and M.E. McManus, Functional characterisation of two human 
sulphotransferase cDNAs that encode monoamine- and phenol-sulphating forms of phenol 
sulphotransferase: substrate kinetics, thermal-stability and inhibitor-sensitivity studies. Biochem. J. 302 
(1994), pp. 497–502.  
6. F.A.O. Marston, The purification of eukaryotic polypeptides synthesized in E. coli. Biochem. J. 240 (1986), pp. 
1–12.  
7. F.P. Guengerich, E.M.J. Gillam and T. Shimada, New applications of bacterial systems to problems in toxicology. 
Crit. Rev. Toxicol. 26 (1996), pp. 551–583.  
8. E.M.J. Gillam, T. Baba, B.-R. Kim, S. Ohmori and F.P. Guengerich, Expression of modified human cytochrome 
P450 3A4 in E. coli and purification and reconstitution of the enzyme. Arch. Biochem. Biophys. 305 
(1993), pp. 123–131.  
9. M.P. Weiner, C. Anderson, B. Jerpseth, S. Wells, B. Johnson-Brown and P. Vaillancourt, Studier pET system 
vectors and hosts. Strategies 7 (1994), pp. 41–43. 
10. A. Foldes and J.L. Meek, Rat brain phenolsulfotransferase-partial purification and some properties. Biochim. 
Biophys. Acta 327 (1973), pp. 365–373. 
11. D. Cruickshank, L.N. Sansom, M.E. Veronese, B. Mojarrabi, M.E. McManus and X. Zhu, cDNA expression 
studies of rat liver aryl sulphotransferase. Biochem. Biophys. Res. Commun. 191 (1993), pp. 295–301.  
 
